BioAtla

Key facts

Employees

51

Industries

Biotechnology, Health Care, Therapeutics

Status

Public (BCAB)

LinkedIn

Company page

Recent activity at BioAtla

• Oct 15, 2026: SEC 8-K (1.01):
• Sep 23, 2026: SEC 8-K (5.02): On September 25, 2026, Dr. Eric Sievers resigned from his role as Chief Medical Officer of BioAtla, Inc. to pursue interests outside of the company, but will serve as a consultant under a new Consulting Agreement. This agreement establishes a one-time payment of $159,000 for Dr. Sievers contingent upon the company achieving specific capital raising milestones by December 31, 2026. The transition is significant as it alters the company's leadership while allowing Dr. Sievers to continue contributing his expertise during the consulting period, which extends through June 30, 2027.
• Apr 02, 2026: SEC 8-K (8.01): On April 2, 2026, BioAtla, Inc. filed a certificate of merger to finalize a previously announced Agreement and Plan of Merger with BA Merger Sub, Inc. This transaction is set to take effect on April 6, 2026, at 12:01 a.m. Eastern Time. Upon the merger's effectiveness, each fifty shares of BioAtla's common stock will be converted into one share of the surviving corporation. This strategic merger is significant for the company as it consolidates its operational structure and aims to streamline its stock ownership after the transaction is completed.
• Mar 31, 2026: SEC 8-K (7.01): On March 31, 2026, BioAtla, Inc. updated its corporate presentation intended for use in meetings with various potential investors, analysts, and strategic partners. This Corporate Presentation, dated the same day, outlines the company's strategic initiatives and performance metrics, aiming to attract investment interest. The disclosure includes an attached Exhibit 99.2, which contains the detailed presentation and is provided for informational purposes, clarifying that it is not deemed filed under the Securities Act or the Exchange Act. This update signifies the company's proactive approach to engaging with stakeholders and communicating its value proposition in a competitive market.
• Mar 23, 2026: SEC 8-K (5.02): On March 20, 2026, BioAtla, Inc. approved a retention bonus program for Jay M. Short, Ph.D., the Company’s Chief Executive Officer, due to the absence of a bonus plan for the first eight months of 2026. The bonuses for Mr. Christian Vasquez, Chief Financial Officer, and Dr. Eric Sievers, Chief Medical Officer, were approved on March 17, 2026, with payouts contingent on achieving specific financial and capital-raising milestones by May 31, 2026, and August 31, 2026. Mr. Vasquez’s bonuses could reach $186,110 while Dr. Sievers’s could reach $265,315, based on performance exceeding predetermined targets. The programs reflect the Company's strategic initiative to retain key executives amidst a backdrop of unmet performance milestones in 2025, indicating a significant focus on aligning executive compensation with future company performance.
• Mar 02, 2026: SEC 8-K (5.02): Richard Waldron’s employment as Chief Financial Officer of the Company will terminate effective March 2, 2026. The Company has agreed to provide Mr. Waldron severance benefits, including a prorated salary and extended exercise period for his stock options, in exchange for a general release of claims. Concurrently, Chris Vasquez has been appointed as the new Chief Financial Officer, effective the same day. Mr. Vasquez brings over 20 years of experience in finance and was previously serving as Chief Accounting Officer. There are no family relationships or undisclosed arrangements involving Mr. Vasquez in connection with his appointment.
• Feb 09, 2026: SEC 8-K (8.01): On February 8, 2026, BioAtla, Inc. received notification from Nasdaq's Office of General Counsel regarding a review of a Delist Determination made on February 6, 2026, which called for the suspension of trading of the company's securities effective February 10, 2026, due to non-compliance with Nasdaq Listing Rules. The Listing Council has decided to stay the suspension and delisting action while it reviews the case, which could take weeks to months. The company is contesting the decision, claiming that Nasdaq's policies and lack of timely compliance confirmation have caused significant harm to its operations. The outcome of the review is uncertain, and there are serious implications for the company's ongoing trading status on Nasdaq.
• Feb 06, 2026: SEC 8-K (7.01):
• Jan 30, 2026: SEC 8-K (8.01):
• Jan 12, 2026: SEC 8-K (8.01): On January 12, 2026, the Company reconvened its Special Meeting of stockholders to solicit additional proxies for the approval of a Reverse Stock Split Proposal due to insufficient votes during the originally convened meeting on December 30, 2025. The Stock Issuance Proposal was approved, but the Reverse Stock Split Proposal failed to garner the required two-thirds vote needed for approval, despite over 70% of proxies supporting it. The meeting was subsequently adjourned without the proposal being passed. This situation indicates ongoing governance and strategic maneuvers as the Company attempts to manage its capital structure.

Leadership

• Lauri Koorits, CEO

Verified email and direct lines for BioAtla’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.

Companies similar to BioAtla

• Jasper Therapeutics · Biotechnology, Health Care, Therapeutics
• Genetix Biotherapeutics · Biotechnology, Health Care, Therapeutics
• MeiraGTx Holdings plc · Biotechnology, Health Care, Therapeutics
• Apollomics · Biotechnology, Health Care, Therapeutics
• Transgene · Biotechnology, Health Care, Therapeutics

About BioAtla: questions and answers

Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy